Daiichi Sankyo has made the development of RNA-based therapeutics and vaccines one of the pillars of its R&D operations and has turned to start-up Depixus to accelerat
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.